Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.47 |
| ▸ | CES1 | P23141 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.43 |
| ▸ | MEN1 | O00255 | 4/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 4/20 | 0.43 |
| ▸ | MAPT | P10636 | 4/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | CYP11B1 | P15538 | 7/20 | 0.38 |
| ▸ | CYP11B2 | P19099 | 6/20 | 0.38 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.38 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | DHODH | Q02127 | 2/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 3/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | PLIN1 | O60240 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2083176 | 1.00 | CES2 (0.47) | CES2CES1KMT2AMEN1NPSR1 | |
| SCHEMBL2083177 | 1.00 | CES2 (0.47) | CES2CES1KMT2AMEN1NPSR1 | |
| SCHEMBL2079689 | 0.91 | MEN1 (0.43) | CES2CES1KMT2AMEN1NPSR1 | |
| SCHEMBL2079686 | 0.91 | MEN1 (0.43) | CES2CES1KMT2AMEN1NPSR1 | |
| SCHEMBL116506 | 0.90 | KMT2A (0.40) | CES2CES1KMT2AMEN1NPSR1 | |
| SCHEMBL1476623 | 0.90 | KMT2A (0.40) | CES2CES1KMT2AMEN1NPSR1 | |
| SCHEMBL1476620 | 0.90 | KMT2A (0.40) | CES2CES1KMT2AMEN1NPSR1 | |
| SCHEMBL4567521 | 0.86 | MEN1 (0.40) | KMT2AMEN1NPSR1MAPTLMNA | |
| SCHEMBL3695378 | 0.86 | MEN1 (0.40) | KMT2AMEN1NPSR1MAPTLMNA | |
| SCHEMBL9561731 | 0.86 | MEN1 (0.40) | KMT2AMEN1NPSR1MAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120122804-A1 | SUBSTITUTED QUINOBENZOXAZINE ANALOGS | CYLENE PHARMACEUTICALS, INC. (US) | 2012-05-17 | — | — | US | disclosed |
| US-20120122804-A1 | SUBSTITUTED QUINOBENZOXAZINE ANALOGS | CYLENE PHARMACEUTICALS, INC. (US) | 2012-05-17 | — | — | US | disclosed |
| US-20110065687-A1 | HYDRAZIDE COMPOUNDS AND USES THEREOF | SENHWA BIOSCIENCES, INC. (TW) | 2011-03-17 | — | — | US | disclosed |
| US-20110065687-A1 | HYDRAZIDE COMPOUNDS AND USES THEREOF | SENHWA BIOSCIENCES, INC. (TW) | 2011-03-17 | — | — | US | disclosed |
| US-7612063-B2 | Substituted quinobenzoxazine analogs | CYLENE PHARMACEUTICALS, INC. (US) | 2009-11-03 | — | — | US | disclosed |
| US-7612063-B2 | Substituted quinobenzoxazine analogs | CYLENE PHARMACEUTICALS, INC. (US) | 2009-11-03 | — | — | US | disclosed |
| US-7507727-B2 | Substituted quinobenzoxazine analogs and methods of using thereof | CYLENE PHARMACEUTICALS, INC. (US) | 2009-03-24 | — | — | US | disclosed |
| US-7507727-B2 | Substituted quinobenzoxazine analogs and methods of using thereof | CYLENE PHARMACEUTICALS, INC. (US) | 2009-03-24 | — | — | US | disclosed |
| WO-2008131134-A1 | HYDRAZIDE COMPOUNDS AND USES THEREOF | CYLENE PHARMACEUTICALS, INC. (US) | 2008-10-30 | — | — | WO | disclosed |
| US-20080261963-A1 | SUBSTITUTED QUINOBENZOXAZINE ANALOGS | CYLENE PHARMACEUTICALS, INC. | 2008-10-23 | — | — | US | disclosed |
| US-20080261963-A1 | SUBSTITUTED QUINOBENZOXAZINE ANALOGS | CYLENE PHARMACEUTICALS, INC. | 2008-10-23 | — | — | US | disclosed |
| US-7381720-B2 | Substituted quinobenzoxazine analogs | CYLENE PHARMACEUTICALS, INC. (US) | 2008-06-03 | — | — | US | disclosed |
| US-7381720-B2 | Substituted quinobenzoxazine analogs | CYLENE PHARMACEUTICALS, INC. (US) | 2008-06-03 | — | — | US | disclosed |
| US-7354916-B2 | Substituted quinobenzoxazine analogs | CYLENE PHARMACEUTICALS (US) | 2008-04-08 | — | — | US | disclosed |
| US-7354916-B2 | Substituted quinobenzoxazine analogs | CYLENE PHARMACEUTICALS (US) | 2008-04-08 | — | — | US | disclosed |
| US-7326702-B2 | Substituted quinobenzoxazine analogs | CYLENE PHARMACEUTICALS, INC. (US) | 2008-02-05 | — | — | US | disclosed |
| US-7326702-B2 | Substituted quinobenzoxazine analogs | CYLENE PHARMACEUTICALS, INC. (US) | 2008-02-05 | — | — | US | disclosed |
| US-20070043039-A1 | Substituted quinobenzoxazine analogs | CYLENE PHARMACEUTICALS, INC. | 2007-02-22 | — | — | US | disclosed |
| US-20070043039-A1 | Substituted quinobenzoxazine analogs | CYLENE PHARMACEUTICALS, INC. | 2007-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080261963-A1 | SUBSTITUTED QUINOBENZOXAZINE ANALOGS | CYP3A5, UGT2B7, CYP2D6 | CES2 94/4885CES1 677/4885KMT2A 1689/4885 |
| US-20120122804-A1 | SUBSTITUTED QUINOBENZOXAZINE ANALOGS | CYP3A5, UGT2B7, CYP2D6 | CES2 94/4885CES1 677/4885KMT2A 1689/4885 |
| US-20070043039-A1 | Substituted quinobenzoxazine analogs | TP53, CCNY, ACIN1 | CES2 1051/4885CES1 2413/4885KMT2A 1533/4885 |
| US-20110065687-A1 | HYDRAZIDE COMPOUNDS AND USES THEREOF | EIF2AK2, DDX21, POLI | CES2 4592/4885CES1 4741/4885KMT2A 1555/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.